Evidence map›Paper›PMID 29338788›Full record

ArticleStem cell research & therapy2018

High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources.

Eliana Amati, Omar Perbellini, Gianluca Rotta, Martina Bernardi, Katia Chieregato, Sabrina Sella, Francesco Rodeghiero, Marco Ruggeri, Giuseppe Astori

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Contribution ofCurrent issues in molecular biology · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. CD317Stem cell research & therapy · 2024
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Stem cell therapy: A promising treatment for COVID-19.World journal of clinical cases · 2021
    Review
  15. Review
  16. Review
  17. Review
  18. Immuno-comparative screening of adult-derived human liver stem/progenitor cells for immune-inflammatory-associated molecules.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Article
  19. Is COVID-19 a New Hematologic Disease?Stem cell reviews and reports · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eliana AmatiAdvanced Cellular Therapy Laboratory, Hematology Unit, S. Bortolo Hospital, ULSS 8 Berica, Contra' San Francesco 41, 36100, Vicenza, Italy.
Omar PerbelliniAdvanced Cellular Therapy Laboratory, Hematology Unit, S. Bortolo Hospital, ULSS 8 Berica, Contra' San Francesco 41, 36100, Vicenza, Italy.
Gianluca RottaBD Biosciences Italia, Milano, Italy.
Martina BernardiAdvanced Cellular Therapy Laboratory, Hematology Unit, S. Bortolo Hospital, ULSS 8 Berica, Contra' San Francesco 41, 36100, Vicenza, Italy.
Katia ChieregatoAdvanced Cellular Therapy Laboratory, Hematology Unit, S. Bortolo Hospital, ULSS 8 Berica, Contra' San Francesco 41, 36100, Vicenza, Italy.
Sabrina SellaAdvanced Cellular Therapy Laboratory, Hematology Unit, S. Bortolo Hospital, ULSS 8 Berica, Contra' San Francesco 41, 36100, Vicenza, Italy.
Francesco RodeghieroHematology Project Foundation, Vicenza, Italy.
Marco RuggeriAdvanced Cellular Therapy Laboratory, Hematology Unit, S. Bortolo Hospital, ULSS 8 Berica, Contra' San Francesco 41, 36100, Vicenza, Italy.
Giuseppe AstoriAdvanced Cellular Therapy Laboratory, Hematology Unit, S. Bortolo Hospital, ULSS 8 Berica, Contra' San Francesco 41, 36100, Vicenza, Italy. astori@hemato.ven.it.
Ospedale San Bortolo · ITFondazione Progetto Ematologia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stromal cells (MSC) are a heterogeneous population of multipotent progenitors used in the clinic because of their immunomodulatory properties and their ability to differentiate into multiple mesodermal lineages. Although bone marrow (BM) remains the most common MSC source, cord blood (CB) can be collected noninvasively and without major ethical concerns. Comparative studies comprehensively characterizing the MSC phenotype across several tissue sources are still lacking. This study provides a 246-antigen immunophenotypic analysis of BM- and CB-derived MSC aimed at identifying common and strongly expressed MSC markers as well as the existence of discriminating markers between the two sources.

methodsBM-MSC (n = 4) were expanded and analyzed as bulk (n = 6) or single clones isolated from the bulk culture (n = 3). CB-MSC (n = 6) were isolated and expanded as single clones in 5/6 samples. The BM-MSC and CB-MSC phenotype was investigated by flow cytometry using a panel of 246 monoclonal antibodies. To define the markers common to both sources, those showing the smallest variation between samples (coefficient of variation of log

resultsBased on HCL, 18 markers clustered as strongly expressed in BM-MSC and CB-MSC, including alpha-smooth muscle antigen (SMA), beta-2-microglobulin, CD105, CD13, CD140b, CD147, CD151, CD276, CD29, CD44, CD47, CD59, CD73, CD81, CD90, CD98, HLA-ABC, and vimentin. All except CD140b and alpha-SMA were suitable for the specific identification of ex-vivo expanded MSC. Notably, only angiotensin-converting enzyme (CD143) was exclusively expressed on BM-MSC. CD143 expression was tested on 10 additional BM-MSC and CB-MSC and on 10 umbilical cord- and adipose tissue-derived MSC samples, confirming that its expression is restricted to adult sources.

conclusionsThis is the first study that has comprehensively compared the phenotype of BM-MSC and CB-MSC. We have identified markers that could complement the minimal panel proposed for the in-vitro MSC definition, being shared and strongly expressed by BM- and CB-derived MSC. We have also identified CD143 as a marker exclusively expressed on MSC derived from adult tissue sources. Further studies will elucidate the biological role of CD143 and its potential association with tissue-specific MSC features.

Indexed as

AdultAntigens, CDBiomarkersBone Marrow CellsCell ProliferationCells, CulturedFemaleFetal BloodFlow CytometryHumansMaleMesenchymal Stem CellsMiddle AgedPeptidyl-Dipeptidase APhenotypeUmbilical CordACE protein, humanAntigens, CDBiomarkersPeptidyl-Dipeptidase AAngiotensin-converting enzymeBone marrowCD143Cord bloodFlow cytometryHematopoietic progenitor cell markerHigh-throughput screeningImmunophenotypeLyoplateMesenchymal stromal cells

Identifiers

PMID29338788
PMCPMC5771027
OpenAlexW2782741780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.